Scleroderma

Abatacept Well-Tolerated But Has Minimal Benefit in Diffuse Cutaneous Systemic Sclerosis

Researchers assessed the safety and efficacy of abatacept in patients with diffuse cutaneous systemic sclerosis (dcSSc).

Validating REVEAL: Can Scores Accurately Predict Survival in SSc-PAH?

Researchers sought to determine the benefits of using a prognostic equation and risk score calculator to predict survival in systemic sclerosis-associated PAH.

Validating REVEAL: Can Scores Accurately Predict Survival in SSc-PAH?

Researchers sought to determine the benefits of using a prognostic equation and risk score calculator to predict survival in systemic sclerosis-associated PAH.

SSc-PAH Risk Category Improves With Ambrisentan and Tadalafil Combination Therapy

Combination treatment with ambrisentan and tadalafil is associated with a reduced mortality risk profile in patients with scleroderma-associated pulmonary arterial hypertension.

Red Cell Distribution Width May Be a Biomarker for Early Pulmonary Hypertension in SSc

Red cell distribution width may help detect early incident PH in patients who are at high risk for PH development.

Progressive Skin Fibrosis in SSc Associated With Lung Function Decline

In patients with diffuse cutaneous systemic sclerosis, developing progressive skin fibrosis within 1 year is associated with a decline in lung function and worse survival.

Rituximab Safe, Effective in Patients With Systemic Sclerosis

Rituximab treatment improved skin fibrosis in a cohort of patients with SSc, but no significant change was observed in lung fibrosis.

SSc-PAH Survival Improves With Combination Sequential Therapy

Patients with systemic sclerosis-associated pulmonary arterial hypertension who were given combination sequential therapy had improved survival rates compared with patients receiving upfront combination or monotherapy.

Pulmonary Hypertension Often Occurs Early After SSc-ILD Diagnosis

Investigators examined the prevalence, characteristics, treatment, and outcomes for patients with pulmonary hypertension in a systemic-sclerosis-associated interstitial lung disease cohort.

Reduced Right Ventricular Output Reserve Observed in SSc With Elevated PAP

Investigators examined right ventricular function and pulmonary arterial compliance at rest and during exercise in patients with systemic sclerosis with normal or mildly elevated mean pulmonary artery pressures, or with manifest pulmonary hypertension.